394 related articles for article (PubMed ID: 29453610)
1. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis.
Hill LA; Delmonte RJ; Andrews B; Richards L; Soto R; Collier S; Kuo A; Cachay E
Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1378-1383. PubMed ID: 29975243
[TBL] [Abstract][Full Text] [Related]
3. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study.
Kieran JA; Norris S; O'Leary A; Walsh C; Merriman R; Houlihan D; McCormick PA; McKiernan S; Bergin C; Barry M
BMC Infect Dis; 2015 Oct; 15():471. PubMed ID: 26503519
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Pharmacy-Led Hepatitis C Direct-Acting Antiviral Utilization Management at a Veterans Affairs Medical Center.
Yang S; Britt RB; Hashem MG; Brown JN
J Manag Care Spec Pharm; 2017 Mar; 23(3):364-369. PubMed ID: 28230455
[TBL] [Abstract][Full Text] [Related]
6. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
[TBL] [Abstract][Full Text] [Related]
9. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
[TBL] [Abstract][Full Text] [Related]
10. An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!
Rubin A; Berenguer M
Liver Transpl; 2010 Jun; 16(6):697-700. PubMed ID: 20517902
[No Abstract] [Full Text] [Related]
11. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
Younossi ZM; Park H; Dieterich D; Saab S; Ahmed A; Gordon SC
Liver Int; 2017 May; 37(5):662-668. PubMed ID: 27804195
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
13. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
14. Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents.
Moon AM; Green PK; Berry K; Ioannou GN
Aliment Pharmacol Ther; 2017 May; 45(9):1201-1212. PubMed ID: 28271521
[TBL] [Abstract][Full Text] [Related]
15. Economic burden associated with patients diagnosed with hepatitis C.
McCombs JS; Yuan Y; Shin J; Saab S
Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
[TBL] [Abstract][Full Text] [Related]
16. Trends in Treatment Uptake and Provider Specialty for Hepatitis C Virus (HCV) Infection in the Veterans Affairs Healthcare System: Results From the Electronically Retrieved Cohort of HCV-Infected Veterans (ERCHIVES).
Butt AA; Yan P; Lo Re Iii V; Shaikh OS; Ross DB
Clin Infect Dis; 2019 Feb; 68(5):857-859. PubMed ID: 30137251
[TBL] [Abstract][Full Text] [Related]
17. Curing Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs.
Belperio PS; Chartier M; Ross DB; Alaigh P; Shulkin D
Ann Intern Med; 2017 Oct; 167(7):499-504. PubMed ID: 28973196
[TBL] [Abstract][Full Text] [Related]
18. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data.
Marcellusi A; Viti R; Kondili LA; Rosato S; Vella S; Mennini FS;
Pharmacoeconomics; 2019 Feb; 37(2):255-266. PubMed ID: 30378086
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
20. Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi.
Schiff L
Clin Ther; 2015 May; 37(5):1092-112. PubMed ID: 25850880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
